KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Share-based Compensation (2016 - 2025)

NovoCure (NVCR) has disclosed Share-based Compensation for 12 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 68.42% to $19.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $104.8 million through Dec 2025, down 34.49% year-over-year, with the annual reading at $104.8 million for FY2025, 34.49% down from the prior year.
  • Share-based Compensation hit $19.8 million in Q4 2025 for NovoCure, down from $29.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $62.8 million in Q4 2024 to a low of $17.4 million in Q4 2023.
  • Historically, Share-based Compensation has averaged $29.1 million across 5 years, with a median of $27.1 million in 2021.
  • Biggest five-year swings in Share-based Compensation: surged 259.89% in 2024 and later plummeted 68.42% in 2025.
  • Year by year, Share-based Compensation stood at $22.4 million in 2021, then soared by 32.97% to $29.8 million in 2022, then crashed by 41.45% to $17.4 million in 2023, then soared by 259.89% to $62.8 million in 2024, then tumbled by 68.42% to $19.8 million in 2025.
  • Business Quant data shows Share-based Compensation for NVCR at $19.8 million in Q4 2025, $29.3 million in Q3 2025, and $26.1 million in Q2 2025.